Marinomed has already achieved many milestones in its short history. The selected scientific publications and press releases provide information on the most important events to date.
September 08, 2020
Marinomed applies for drug approval for new decongestant nasal spray in Europe
August 27, 2020
Marinomed with record sales in H1 2020 - high growth opportunities with virus blocker in the fight against coronavirus
July 16, 2020
Marinomed Biotech AG: Carragelose® effective against SARS-CoV-2 in cell culture assays
June 02, 2020
Marinomed expands into Italy and broadens its portfolio
May 26, 2020
Marinomed with significant sales increase in Q1 2020
May 14, 2020
Marinomed: Postponement of the Annual General Meeting to September 17, 2020
April 28, 2020
Marinomed receives FFG funding to research SARS-CoV-2 therapy based on Carragelose®
April 16, 2020
Marinomed with record sales in 2019 and positive outlook for 2020
March 09, 2020
Marinomed Biotech AG extends the range of Marinosolv® applications
February 06, 2020
Marinosolv® technology successfully used in preclinical study in severe eye disease Neurotrophic keratopathy
January 22, 2020
Marinomed Biotech AG: Sellers complete accelerated bookbuilding; 105,000 Marinomed shares have been sold for EUR 95 per share
January 22, 2020
Marinomed Biotech AG: Shareholders offer shares by way of an accelerated bookbuilding
November 29, 2019
Marinomed paves the way for long term growth in Q1 3/2019
November 26, 2019
Marinomed Biotech AG: Detailed clinical data show rapid onset of action of Budesolv to alleviate hay fever
October 16, 2019
Marinomed Biotech AG: aws Mittelstandsfonds and Invest AG sold Marinomed shares by way of an accelerated bookbuilding for EUR 95 per share to institutional investors
October 15, 2019
Marinomed Biotech AG: aws Mittelstandsfonds and Invest AG start partial sale of Marinomed shares by way of an accelerated bookbuilding
August 30, 2019
Marinomed: Investments in strong technology portfolio in first half-year 2019
May 29, 2019
Marinomed: Focus on future investments in Q1 2019
May 15, 2019
Marinomed Biotech AG: Budesolv with a strongly decreased dose of the active ingredient compared to the marketed product Rhinocort Aqua shows pronounced efficacy already after first application – clinical validation of the Marinosolv® platform
April 30, 2019
In 2018, Marinomed set the course for accelerated growth
April 23, 2019
Marinomed Biotech AG announces top line results of the Phase III study for Budesolv
February 28, 2019
Marinomed Biotech AG: Greenshoe option fully exercised
February 26, 2019
Marinomed receives EUR 15m EIB financing
February 18, 2019
Marinomed announces result of conversion of convertible bonds
January 29, 2019
Marinomed sets offer price at 75 Euro per share
January 29, 2019
Marinomed announces strong investor demand and expected offer price
January 23, 2019
Marinomed resumes offer period of the IPO
December 21, 2018
Screening of pivotal clinical trial completed
November 29, 2018
Marinomed suspends offer period of the current IPO
November 28, 2018
Viennese biotech company Marinomed demonstrates the benefits of its patented Marinosolv® technology
November 16, 2018
Marinomed determines IPO timeline and terms
November 05, 2018
Marinomed intends to conduct an IPO on the Vienna Stock Exchange
October 19, 2018
Initiation of Phase III clinical trial
August 29, 2018
Vienna-based biotech company Marinomed on a growth path
August 07, 2018
Vienna-based Biotech Company Marinomed obtains EU-wide Certification for new cold Medication
July 31, 2018
Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomed strengthens its management team – Company reports strong growth.
November 27, 2017